Thursday, December 12, 2013

Prothena sign a big $600 million deal with Roche for anti-body based Parkinson's disease pre-clinical program

The deal between Roche and Prothena announced on Wednesday 12/11/2013 values the antibody PRX002, which targets the alpha-synuclein protein thought to be behind the formation of Lewy bodies and part of the pathology if the disease, at $600 million.

This is great news for everyone in the Parkinson's space at it shows that there is interest from "big Pharma" in something other than small molecule dopamine replacement strategies, and in particular more "biological" approaches"

No comments:

Post a Comment